ABSTRACT Introduction: Immunotherapy led to increased survival in advanced non-small cell lung cancer; however, it has also increased treatment costs. In this study, real-world data was used to evaluate the average cost of treatment of patients with lung cancer. Material and Methods: This is a retrospective study that extracted patient-level...
ABSTRACT Introduction: Older adults require attention to risks of treatment toxicity. The purpose of this study was to evaluate epidemiological data and clinical outcomes of patients with lung cancer treated with non-curative intent assessed by geriatric assessment (GA) and restricted access to new therapies. Methods: We evaluated older adults with non-small cell...
Central nervous system metastases of lung adenocarcinoma harboring EGFR-activating mutations: survival results from a multidisciplinary approach, including EGFR-TKIs
ABSTRACT Objectives: Central nervous system (CNS) metastases are frequent in advanced lung adenocarcinomas harboring EGFR-activating mutations. However, the best treatment approach must be defined. We aimed to evaluate the effectiveness of a multidisciplinary approach for CNS metastases in patients previously untreated with EGFR tyrosine kinase inhibitors (EGFRTKIs). Methods: We performed a retrospective...
ABSTRACT Objectives: Osimertinib is a third-generation EGFR inhibitor with activity against both sensitizing and resistance mutations. Following results of the phase III study, AURA3, which led to the approval of osimertinib worldwide, we have conducted ASTRIS with the aim of confirming the efficacy and safety of osimertinib. Methods: This is a phase...
ABSTRACT Concerned with the evolution of COVID-19 in Brazil and its impact on our health system and oncology surgical assistance, the authors performed a review and suggested strategies for approach based on current evidence.
Prognostic impact of and mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil EGFR KRAS
ABSTRACT Objective: To evaluate the genetic tests is fundamental for the adequate treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI). Given that access to this evaluation is still limited for those who depend on the Brazilian Public Health System, it seems important to provide regulatory agencies with...
